Related references
Note: Only part of the references are listed.Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial
David J. Chung et al.
ONCOIMMUNOLOGY (2018)
Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination
Kazuyoshi Takeda et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report
Mariana Aris et al.
FRONTIERS IN IMMUNOLOGY (2018)
Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants
Maria B. Pampena et al.
FRONTIERS IN IMMUNOLOGY (2018)
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma
Alexander C. Hopkins et al.
JCI INSIGHT (2018)
Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Maria Parkhurst et al.
CLINICAL CANCER RESEARCH (2017)
Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients
Philippe O. Gannon et al.
CLINICAL CANCER RESEARCH (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase ii Study of adjuvant immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose interferon alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: a Single institution, randomized Study
Jose Mordoh et al.
FRONTIERS IN IMMUNOLOGY (2017)
Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release
Maria B. Pampena et al.
FRONTIERS IN IMMUNOLOGY (2017)
Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
Nobuhiro Tsuchiya et al.
ONCOIMMUNOLOGY (2017)
Overcoming resistance to BRAF inhibitors
Imanol Arozarena et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Overview of methodologies for T-cell receptor repertoire analysis
Elisa Rosati et al.
BMC BIOTECHNOLOGY (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo
Aude G. Chapuis et al.
SCIENCE IMMUNOLOGY (2017)
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
Harriet M. Kluger et al.
CLINICAL CANCER RESEARCH (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report
Mariana Aris et al.
FRONTIERS IN IMMUNOLOGY (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
David L. Bajor et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Modeling the Mycobacterium tuberculosis granuloma - the critical battlefield in host immunity and disease
Evelyn Guirado et al.
FRONTIERS IN IMMUNOLOGY (2013)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Veronique Corbiere et al.
CANCER RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cutaneous Metastases of Malignant Melanoma: A Clinicopathologic Study of 192 Cases With Emphasis on the Morphologic Spectrum
Jose A. Plaza et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2010)
Mycobacterial lipomannan induces granuloma macrophage fusion via a TLR2-dependent, ADAM9- and β1 integrin-mediated pathway
Marie-Pierre Puissegur et al.
JOURNAL OF IMMUNOLOGY (2007)
Langhans giant cells from M-tuberculosis-induced human granulomas cannot mediate mycobacterial uptake
G. Lay et al.
JOURNAL OF PATHOLOGY (2007)
A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients
Maria M. Barrio et al.
JOURNAL OF IMMUNOTHERAPY (2006)
New insights into the function of granulomas in human tuberculosis
T Ulrichs et al.
JOURNAL OF PATHOLOGY (2006)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity
D Valmori et al.
JOURNAL OF IMMUNOLOGY (2002)
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma
Y Kawakami et al.
JOURNAL OF IMMUNOTHERAPY (2000)
Share Paper
